NCT07032103

Brief Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
32mo left

Started Jun 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress60%
Jun 2022Dec 2028

Study Start

First participant enrolled

June 1, 2022

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

June 13, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 22, 2025

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2028

Last Updated

June 22, 2025

Status Verified

June 1, 2025

Enrollment Period

6.6 years

First QC Date

June 13, 2025

Last Update Submit

June 13, 2025

Conditions

Lymphoma

Keywords

lymphomaprognosis

Outcome Measures

Primary Outcomes (2)

  • Reponse rate

    Repsonse to the ist line treatment

    3 months after the completion of treatment

  • Response

    response to treatment

    3 months after chemotherapy

Interventions

ImmunochemotherapyDRUG

Systemic chemotherapy with curative intent

Also known as: Supportive treatment

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled

You may qualify if:

  • Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
  • years
  • Patients requiring systemic chemotherapy with curative intent
  • Written informed consent

You may not qualify if:

  • Myeloid malignancy
  • Multiple myeloma
  • Patients do not require systemic chemotherapy with curative intent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, 06351, South Korea

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Serum and cell-free DNA from patients' peripheral blood

MeSH Terms

Conditions

Lymphoma

Interventions

Palliative Care

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

Patient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and Services

Central Study Contacts

Seok Jin Kim, MD., PhD.

CONTACT

+82234101766kstwoh@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 13, 2025

First Posted

June 22, 2025

Study Start

June 1, 2022

Primary Completion (Estimated)

December 30, 2028

Study Completion (Estimated)

December 30, 2028

Last Updated

June 22, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations

KR(1)